NCT02784158No Longer AvailableNot Applicable
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Ariad Pharmaceuticals3 sites in 1 countryStarted: May 26, 2016Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- No Longer Available
- Sponsor
- Locations
- 3
Study Overview
Brief Summary
The purpose of this study is to provide brigatinib for those patients with locally advanced and/or metastatic patients with ALK+ NSCLC on an expanded access basis due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have histologically or cytologically confirmed locally advanced or metastatic NSCLC that is determined to have an ALK-rearrangement detected according to local standard procedure.
- •Resistant to or intolerant of at least 1 prior ALK TKI.
- •Recovered from toxicities related to prior anticancer therapy to NCI CTCAE, v4.0) grade ≤
- •Are a male or female patient ≥18 years old.
- •Have adequate organ and hematologic function, as defined by the study protocol.
- •Have Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Have normal QT interval on screening electrocardiogram (ECG) evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 ms in males or ≤470 ms in females.
- •For female patients of childbearing potential, a negative pregnancy test must be documented prior to enrollment (<7 days prior to the first dose).
- •Female and male patients who are fertile must agree to use a highly effective form of contraception as defined by the study protocol.
- •Must provide a signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.
Exclusion Criteria
- •Received an ALK TKI within 10 days prior to the first dose of brigatinib.
- •Received cytotoxic chemotherapy, investigational agents, or radiation within 14 days, except stereotactic radiosurgery (SRS) or stereotactic body radiosurgery.
- •Received prior brigatinib therapy.
- •Received monoclonal antibodies within 30 days of the first dose of brigatinib.
- •Had major surgery within 30 days of the first dose of brigatinib.
- •Have current spinal cord compression.
- •Have significant, uncontrolled, or active cardiovascular disease within 6 months prior to first dose, as defined by the study protocol.
- •Have a history or the presence of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.
- •Have a known or suspected hypersensitivity to brigatinib or its excipients.
- •Have any condition or illness that, in the opinion of the investigator, would compromise patient safety.
- •Are pregnant or breastfeeding.
- •Are eligible for and have reasonable access to participate in another ongoing brigatinib clinical study.
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Available
Not Applicable
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAcute Lymphoblastic LeukemiaMantle Cell LymphomaNCT05776134Kite, A Gilead Company
Recruiting
Phase 2
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibNSCLCNCT06620835Groupe Francais De Pneumo-Cancerologie45
No Longer Available
Not Applicable
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) MutationsNCT03409081Astellas Pharma Global Development, Inc.
Approved For Marketing
Not Applicable
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GISTGIST - Gastrointestinal Stromal TumorNCT04148092Deciphera Pharmaceuticals, LLC
Available
Not Applicable
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular LymphomaNCT05776160Kite, A Gilead Company